Andrey Olegovich Nefedov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrey Olegovich Nefedov has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Andrey I. Arseniev
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health Russia
9 shared publications - Anton Barchuk
Cancer Surveillance Branch, International Agency for Research on Cancer , Lyon
7 shared publications - Piotr Kazimirovich Yablonskii
St. Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of the Russian Federation
6 shared publications - Sergey Nikolaevich Novikov
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Сергей Александрович Тарков
N.N. Petrov National Medicine Research Center of Oncology
6 shared publications - M. M. Mortada
St. Petersburg Research Institute of Phthisiopulmonology
5 shared publications
Latest Publications
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 54-58
Errors and difficulties in diagnosing bronchiolar adenoma
This article presents a rare clinical case of a 65-year-old female patient with bilateral lung lesions who underwent surgery for a ciliated muconodular papillary tumor/bronchiolar adenoma. The article highlights the challenges of differential diagnosis with adenocarcinoma during the preliminary examination stage during surgical planning, as well as the issues that arise during intraoperative examination. Multislice computed tomography data and the results of histological and immunohistochemical studies are presented. The histological features of proximal and distal types of bronchiolar adenoma are discussed. The differential diagnosis of bronchiolar adenoma from mucinous adenocarcinoma is discussed, along with a list of immunohistochemical markers used. Using this case as an example, the author presents the results of molecular genetic studies on bronchiolar adenoma, as well as published data.
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 54-58
Errors and difficulties in diagnosing bronchiolar adenoma
This article presents a rare clinical case of a 65-year-old female patient with bilateral lung lesions who underwent surgery for a ciliated muconodular papillary tumor/bronchiolar adenoma. The article highlights the challenges of differential diagnosis with adenocarcinoma during the preliminary examination stage during surgical planning, as well as the issues that arise during intraoperative examination. Multislice computed tomography data and the results of histological and immunohistochemical studies are presented. The histological features of proximal and distal types of bronchiolar adenoma are discussed. The differential diagnosis of bronchiolar adenoma from mucinous adenocarcinoma is discussed, along with a list of immunohistochemical markers used. Using this case as an example, the author presents the results of molecular genetic studies on bronchiolar adenoma, as well as published data.
- Open Access
- 1 October 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (4) , 162-169
Features and approaches to treating patients with concurrent lung cancer and lymphoproliferative disorders
Background. Epidemiological studies show that the incidence of synchronous multiple primary malignant neoplasms ranges from 2 % to 17 %. the co-occurrence of lung cancer and lymphoma accounts for 15 % of all combinations of lymphoproliferative diseases with malignant neoplasms of other organs. Currently, there is no universally accepted diagnostic and treatment strategy for this patient group. Objective: To present a series of clinical cases demonstrating the significance of a personalized approach in the diagnosis and treatment of patients with the concurrent diagnosis of lung cancer and lymphoproliferative diseases. Case reports. We report two cases of synchronous lung cancer and B-cell lymphoma. In both cases, diagnosis of multiple primary malignancies guided optimal treatment strategies. Conclusion. Lung cancer should be included in the differential diagnosis of pulmonary lesions in patients with chronic leukemia or lymphoma. a thorough examination and morphological verification of the identified changes in this group of patients will help to choose the correct treatment strategy.
- 1 October 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (4) , 162-169
Open AccessFeatures and approaches to treating patients with concurrent lung cancer and lymphoproliferative disorders
Background. Epidemiological studies show that the incidence of synchronous multiple primary malignant neoplasms ranges from 2 % to 17 %. the co-occurrence of lung cancer and lymphoma accounts for 15 % of all combinations of lymphoproliferative diseases with malignant neoplasms of other organs. Currently, there is no universally accepted diagnostic and treatment strategy for this patient group. Objective: To present a series of clinical cases demonstrating the significance of a personalized approach in the diagnosis and treatment of patients with the concurrent diagnosis of lung cancer and lymphoproliferative diseases. Case reports. We report two cases of synchronous lung cancer and B-cell lymphoma. In both cases, diagnosis of multiple primary malignancies guided optimal treatment strategies. Conclusion. Lung cancer should be included in the differential diagnosis of pulmonary lesions in patients with chronic leukemia or lymphoma. a thorough examination and morphological verification of the identified changes in this group of patients will help to choose the correct treatment strategy.
- Open Access
- 24 July 2025
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 16 (2) , 110-115
Mediastinal hemangioma: how to avoid surgical resection?
Mediastinal hemangioma is a rare benign tumor which can sometimes mimic the clinical presentation and radiological findings of malignant tumors. Here we present a rare case of cavernous hemangioma in the mediastinum in a patient with colorectal cancer, which required histologic verification before onset of treatment. Type of contrast enhancement, presence of drainage veins and calcification are typical characteristics of hemangioma.
- 24 July 2025
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 16 (2) , 110-115
Open AccessMediastinal hemangioma: how to avoid surgical resection?
Mediastinal hemangioma is a rare benign tumor which can sometimes mimic the clinical presentation and radiological findings of malignant tumors. Here we present a rare case of cavernous hemangioma in the mediastinum in a patient with colorectal cancer, which required histologic verification before onset of treatment. Type of contrast enhancement, presence of drainage veins and calcification are typical characteristics of hemangioma.
- Open Access
- 23 April 2025
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Cifra. Клиническая медицина
- No. 4
Some problems of radiation safety in medicine
С ХХ века на глобальный радиационный фон существенное влияние оказывает техногенная деятельность человека. Из антропогенных источников ионизирующего излучения наиболее распространены медицинские – 95-98%, используемые с диагностическими и лечебными целями. Среди лиц, подвергающихся профессиональному облучению, медицинские работники составляют 75%.Радиационная безопасность предполагает совокупность обоснованных практических и теоретических мер, направленных на обеспечение защиты ныне живущего населения и следующих поколений от негативного действия ионизирующего излучения.В задачи обзора входило на основе анализа данных литературы, относящихся к актуальным проблемам радиационной безопасности, оценить некоторые ее проблемы, имеющие отношение к медицине. Описываются область регулирования, методология, цель и основные принципы радиационной безопасности. Рассматриваются статистические, физические и радиобиологические аспекты предмета. Проводится анализ особенностей национального и международного регулирования в этой области. Показано, что радиационная безопасность подразумевает многоуровневую систему, обеспечивающую комплекс мер с всесторонним учетом вероятного вредоносного воздействия ионизирующего излучения на окружающую среду и людей. Отдельное внимание уделяется вопросам дозиметрии и радиационной защиты. Приводится критика некоторых вопросов нормативной базы. Проведенный анализ литературы и существующих нормативов позволил сделать заключение, что достижение необходимого уровня радиационной безопасности сотрудников, пациентов и населения обеспечивается неукоснительным контролем существующих регламентов и норм, безусловным соблюдением законодательно определенных требований к методам радиотерапии и лучевой диагностики, технологиям, дозиметрическому контролю, техническому оснащению и состоянию помещений.
- 23 April 2025
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Cifra. Клиническая медицина
- No. 4
Open AccessSome problems of radiation safety in medicine
С ХХ века на глобальный радиационный фон существенное влияние оказывает техногенная деятельность человека. Из антропогенных источников ионизирующего излучения наиболее распространены медицинские – 95-98%, используемые с диагностическими и лечебными целями. Среди лиц, подвергающихся профессиональному облучению, медицинские работники составляют 75%.Радиационная безопасность предполагает совокупность обоснованных практических и теоретических мер, направленных на обеспечение защиты ныне живущего населения и следующих поколений от негативного действия ионизирующего излучения.В задачи обзора входило на основе анализа данных литературы, относящихся к актуальным проблемам радиационной безопасности, оценить некоторые ее проблемы, имеющие отношение к медицине. Описываются область регулирования, методология, цель и основные принципы радиационной безопасности. Рассматриваются статистические, физические и радиобиологические аспекты предмета. Проводится анализ особенностей национального и международного регулирования в этой области. Показано, что радиационная безопасность подразумевает многоуровневую систему, обеспечивающую комплекс мер с всесторонним учетом вероятного вредоносного воздействия ионизирующего излучения на окружающую среду и людей. Отдельное внимание уделяется вопросам дозиметрии и радиационной защиты. Приводится критика некоторых вопросов нормативной базы. Проведенный анализ литературы и существующих нормативов позволил сделать заключение, что достижение необходимого уровня радиационной безопасности сотрудников, пациентов и населения обеспечивается неукоснительным контролем существующих регламентов и норм, безусловным соблюдением законодательно определенных требований к методам радиотерапии и лучевой диагностики, технологиям, дозиметрическому контролю, техническому оснащению и состоянию помещений.
- Open Access
- 19 December 2024
- Published by ECO-Vector LLC in Digital Diagnostics
- Vol. 5 (4) , 765-783
Assessing the probability of metastatic mediastinal lymph node involvement in patients with non-small cell lung cancer using convolutional neural networks on chest computed tomography
BACKGROUND: Lung cancer is the second most common cancer worldwide, accounting for approximately 20% of all cancer-related deaths and having a 10% 5-year survival rate for very late-stage cases. For the prevalent non-small cell lung cancer (NSCLC), recent guidelines advise staging based on the 8th edition of the TNM classification, highlighting the importance of mediastinal lymph node involvement. While noninvasive methods are generally accurate, they often lack sensitivity, and invasive methods may not be suitable for all patients. Advances in deep learning present potential in solving such problems. However, most research focuses on algorithm development more than clinical relevance. Moreover, none of them addressed individual lymph node malignancies, limiting comprehensive analysis and interpretability and leaving clinicians without sufficient means to validate the results effectively. AIM: To develop a local data-trained and validated algorithm for segmenting each mediastinal lymph node in chest computed tomography (CT) and assessing the probability of its involvement in metastasis. MATERIALS AND METHODS: Initially, IASLC lymph node stations are segmented, providing a bounding box of the mediastinum for further processing. Next, the image is cropped to this box and passed through a second network to identify and mask all visible lymph nodes. Finally, each detected lymph node is extracted, stacked with its mask, and evaluated by a feed-forward network to determine malignancy probabilities. RESULTS: The pipeline achieved an average recall and object Dice Score of 0.74±0.01 and 0.53±0.26 for the clinically relevant lymph node segmentation task. Further, it recorded a 0.73 ROC AUC for predicting a patient’s N-stage, outperforming traditional size-based criteria. CONCLUSIONS: The proposed algorithm enables new research algorithms to optimize the management of patients with nonenlarged intrathoracic lymph nodes, thus improving the quality of medical care for patients with cancer.
- 19 December 2024
- Published by ECO-Vector LLC in Digital Diagnostics
- Vol. 5 (4) , 765-783
Open AccessAssessing the probability of metastatic mediastinal lymph node involvement in patients with non-small cell lung cancer using convolutional neural networks on chest computed tomography
BACKGROUND: Lung cancer is the second most common cancer worldwide, accounting for approximately 20% of all cancer-related deaths and having a 10% 5-year survival rate for very late-stage cases. For the prevalent non-small cell lung cancer (NSCLC), recent guidelines advise staging based on the 8th edition of the TNM classification, highlighting the importance of mediastinal lymph node involvement. While noninvasive methods are generally accurate, they often lack sensitivity, and invasive methods may not be suitable for all patients. Advances in deep learning present potential in solving such problems. However, most research focuses on algorithm development more than clinical relevance. Moreover, none of them addressed individual lymph node malignancies, limiting comprehensive analysis and interpretability and leaving clinicians without sufficient means to validate the results effectively. AIM: To develop a local data-trained and validated algorithm for segmenting each mediastinal lymph node in chest computed tomography (CT) and assessing the probability of its involvement in metastasis. MATERIALS AND METHODS: Initially, IASLC lymph node stations are segmented, providing a bounding box of the mediastinum for further processing. Next, the image is cropped to this box and passed through a second network to identify and mask all visible lymph nodes. Finally, each detected lymph node is extracted, stacked with its mask, and evaluated by a feed-forward network to determine malignancy probabilities. RESULTS: The pipeline achieved an average recall and object Dice Score of 0.74±0.01 and 0.53±0.26 for the clinically relevant lymph node segmentation task. Further, it recorded a 0.73 ROC AUC for predicting a patient’s N-stage, outperforming traditional size-based criteria. CONCLUSIONS: The proposed algorithm enables new research algorithms to optimize the management of patients with nonenlarged intrathoracic lymph nodes, thus improving the quality of medical care for patients with cancer.
- 29 August 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 93, 102654
Sex differences in lung cancer incidence and mortality in Russia in the light of computed tomography usage expansion: breakpoint and age-period-cohort analyses
- 29 August 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 93, 102654
Sex differences in lung cancer incidence and mortality in Russia in the light of computed tomography usage expansion: breakpoint and age-period-cohort analyses
- Open Access
Automatic Lymph Nodes Segmentation and Histological Status Classification on Computed Tomography Scans Using Convolutional Neural Network
A bstract: Lung cancer is the second most common type of cancer worldwide, making up about 20% of all cancer deaths with less than 10% 5-year survival rate for the very late stage. The recent guidelines for the most common non-small-cell lung cancer (NSCLC) type recommend performing staging based on the 8th edition of TNM classification, where the mediastinal lymph node involvement plays a key role. However, most of the non-invasive methods have a very limited level of sensitivity and are relatively accurate, but invasive methods can be contradicted for some patients. Current advances in Deep Learning show great potential in solving such problems. Still, most of these works focus on the algorithmic side of the problem, not the clinical relevance. Moreover, none of them addressed individual lymph node malignancy classification problem, restricting the indirect analysis of the whole study, and limiting the interpretability of the result without giving an option for cliniciansto validate the result. This work mitigates these gaps, proposing a multi-step algorithm for each visible mediastinal lymph node segmentation and assessing the probability of its involvement in themetastatic process, using the results of histological verification on training. The developed pipelineshows 0.74 ± 0.01 average Recall with 0.53 ± 0.26 object Dice Score for the clinically relevant lymph nodes segmentation task and 0.73 ROC AUC for patient’s N-stage prediction, outperformingtraditional size-based criteria.
Open AccessAutomatic Lymph Nodes Segmentation and Histological Status Classification on Computed Tomography Scans Using Convolutional Neural Network
A bstract: Lung cancer is the second most common type of cancer worldwide, making up about 20% of all cancer deaths with less than 10% 5-year survival rate for the very late stage. The recent guidelines for the most common non-small-cell lung cancer (NSCLC) type recommend performing staging based on the 8th edition of TNM classification, where the mediastinal lymph node involvement plays a key role. However, most of the non-invasive methods have a very limited level of sensitivity and are relatively accurate, but invasive methods can be contradicted for some patients. Current advances in Deep Learning show great potential in solving such problems. Still, most of these works focus on the algorithmic side of the problem, not the clinical relevance. Moreover, none of them addressed individual lymph node malignancy classification problem, restricting the indirect analysis of the whole study, and limiting the interpretability of the result without giving an option for cliniciansto validate the result. This work mitigates these gaps, proposing a multi-step algorithm for each visible mediastinal lymph node segmentation and assessing the probability of its involvement in themetastatic process, using the results of histological verification on training. The developed pipelineshows 0.74 ± 0.01 average Recall with 0.53 ± 0.26 object Dice Score for the clinically relevant lymph nodes segmentation task and 0.73 ROC AUC for patient’s N-stage prediction, outperformingtraditional size-based criteria.
- Open Access
- 6 May 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (2)
Brachytherapy in the Treatment of Non-Small Cell Lung Cancer
The literature review is dedicated to analysing the feasibility, efficacy and safety of using brachytherapy in non-small cell lung cancer. A small number of publications highlighting this issue attract attention. It is shown that the method can be implemented with different isotopes and radiation dose rate options from ultra-low to high. There are three main approaches to brachytherapy in thoracic oncology: intraoperative, interstitial and intraluminal. A number of clinical trials, prospective randomised trials and meta-analyses have shown that brachytherapy significantly increases objective response, local control and survival rates in both localised and widespread disease, with acceptable side effects. The focus is on the possibilities of using intraluminal endobronchial brachytherapy in central lung cancer with lesions of the large bronchi and trachea as part of radical, palliative and symptomatic treatment. It has been shown that it is preferable to use equipment with a high dose rate source in order to shorten the duration of the sessions and reduce patient pain. It is a reasonable method when the options of radiotherapy and chemotherapy have been exhausted. It is recommended that the appropriateness of endobronchial brachytherapy be determined on an individual basis. The own data show that median survival in the endobronchial brachytherapy group was 19 months versus 8 months in the no brachytherapy group, 1-year overall survival was 68 % versus 33 %, and 2-year survival was 37 % versus 8 %. One of the indications for palliative use of the method is endobronchial obstruction, especially recurrent. It is recommended that new randomized controlled trials (RCTs) be conducted to evaluate the efficacy and safety of the method. Improvements in brachytherapy outcomes can be achieved through the use of modern high-tech equipment, improved planning systems, radiation dose calculation methods, fractionation mode and optimization of combination with systemic treatment. Литературный обзор посвящен анализу возможности, эффективности и безопасности использования брахитерапии при немелкоклеточном раке легкого. Обращает внимание небольшое количество публикаций, освящающих эту тему. Показано, что метод может быть реализован с разными изотопами и вариантами мощности дозы излучения от сверхнизкой до высокой. В торакальной онкологии могут осуществляться три основных подхода к проведению брахитерапии: интраоперационный, внутритканевой и внутрипросветный. Рядом клинических испытаний, проспективных рандомизированных исследований и мета-анализов доказано, что брахитерапия приводит к существенному увеличению показателей объективного ответа, локального контроля, выживаемости как при локализованных, так и при местнораспространенных и генерализованных процессах с допустимыми побочными эффектами. Акцентировано внимание на возможностях использования внутрипросветной эндобронхиальной брахитерапии при центральном раке легкого с поражением крупных бронхов и трахеи как в рамках радикального, так паллиативного и симптоматического лечения. Показано, что предпочтительней выполнять ее на аппаратах с источником высокой мощности дозы излучения для сокращения срока сеансов и уменьшения тягостных ощущений у больных. Метод является разумной опцией при исчерпанных возможностях дистанционного облучения и химиотерапии. Целесообразность проведения эндобронхиальной брахитерапии рекомендуется определять индивидуально. Собственные данные свидетельствуют, что медиана выживаемости в группе эндобронхиальной брахитерапии достигала 19 месяцев против 8 месяцев в группе без нее, 1-летняя общая выживаемость — 68 % против 33 %, 2-летняя — 37 % против 8 %. Одним из показаний к паллиативному использованию метода является эндобронхиальная обструкция, особенно рецидивная. Рекомендовано проведение новых исследований для оценки эффективности и безопасности метода. Улучшение результатов использования брахитерапии лежит на пути использования современной высокотехнологичной аппаратуры, совершенствования систем планирования, методик подведения доз облучения, режима фракционирования и оптимизации сочетания с системным лечением.
- 6 May 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (2)
Open AccessBrachytherapy in the Treatment of Non-Small Cell Lung Cancer
The literature review is dedicated to analysing the feasibility, efficacy and safety of using brachytherapy in non-small cell lung cancer. A small number of publications highlighting this issue attract attention. It is shown that the method can be implemented with different isotopes and radiation dose rate options from ultra-low to high. There are three main approaches to brachytherapy in thoracic oncology: intraoperative, interstitial and intraluminal. A number of clinical trials, prospective randomised trials and meta-analyses have shown that brachytherapy significantly increases objective response, local control and survival rates in both localised and widespread disease, with acceptable side effects. The focus is on the possibilities of using intraluminal endobronchial brachytherapy in central lung cancer with lesions of the large bronchi and trachea as part of radical, palliative and symptomatic treatment. It has been shown that it is preferable to use equipment with a high dose rate source in order to shorten the duration of the sessions and reduce patient pain. It is a reasonable method when the options of radiotherapy and chemotherapy have been exhausted. It is recommended that the appropriateness of endobronchial brachytherapy be determined on an individual basis. The own data show that median survival in the endobronchial brachytherapy group was 19 months versus 8 months in the no brachytherapy group, 1-year overall survival was 68 % versus 33 %, and 2-year survival was 37 % versus 8 %. One of the indications for palliative use of the method is endobronchial obstruction, especially recurrent. It is recommended that new randomized controlled trials (RCTs) be conducted to evaluate the efficacy and safety of the method. Improvements in brachytherapy outcomes can be achieved through the use of modern high-tech equipment, improved planning systems, radiation dose calculation methods, fractionation mode and optimization of combination with systemic treatment. Литературный обзор посвящен анализу возможности, эффективности и безопасности использования брахитерапии при немелкоклеточном раке легкого. Обращает внимание небольшое количество публикаций, освящающих эту тему. Показано, что метод может быть реализован с разными изотопами и вариантами мощности дозы излучения от сверхнизкой до высокой. В торакальной онкологии могут осуществляться три основных подхода к проведению брахитерапии: интраоперационный, внутритканевой и внутрипросветный. Рядом клинических испытаний, проспективных рандомизированных исследований и мета-анализов доказано, что брахитерапия приводит к существенному увеличению показателей объективного ответа, локального контроля, выживаемости как при локализованных, так и при местнораспространенных и генерализованных процессах с допустимыми побочными эффектами. Акцентировано внимание на возможностях использования внутрипросветной эндобронхиальной брахитерапии при центральном раке легкого с поражением крупных бронхов и трахеи как в рамках радикального, так паллиативного и симптоматического лечения. Показано, что предпочтительней выполнять ее на аппаратах с источником высокой мощности дозы излучения для сокращения срока сеансов и уменьшения тягостных ощущений у больных. Метод является разумной опцией при исчерпанных возможностях дистанционного облучения и химиотерапии. Целесообразность проведения эндобронхиальной брахитерапии рекомендуется определять индивидуально. Собственные данные свидетельствуют, что медиана выживаемости в группе эндобронхиальной брахитерапии достигала 19 месяцев против 8 месяцев в группе без нее, 1-летняя общая выживаемость — 68 % против 33 %, 2-летняя — 37 % против 8 %. Одним из показаний к паллиативному использованию метода является эндобронхиальная обструкция, особенно рецидивная. Рекомендовано проведение новых исследований для оценки эффективности и безопасности метода. Улучшение результатов использования брахитерапии лежит на пути использования современной высокотехнологичной аппаратуры, совершенствования систем планирования, методик подведения доз облучения, режима фракционирования и оптимизации сочетания с системным лечением.
- Open Access
- 1 November 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (4) , 211-222
Impact of perioperative high-protein nutritional support on the quality of life of patients with primary lung cancer: a Russian prospective multicenter comparative study (NUTRILUNC study)
BACKGROUND: Individuals over the age of 70 comprise over half of operable patients with stage 0–IIIA lung cancer. In the early postoperative period of this cohort, pain, fatigue, insomnia, and/or mood disturbances are the four most common symptoms, which can significantly diminish quality of life and functional status. Perioperative nutritional support in such patients, which enhances exercise tolerance, can have a positive impact on their quality of life and socialization. AIM: To assess the effect of perioperative nutritional support using high-protein oral nutrition supplements on the general health and quality of life of non-small cell lung cancer patients during the postoperative period. MATERIALS AND METHODS: Patients with primary non-small cell lung cancer (n=112, 69 males), aged 57.2±8.2, who were awaiting lung surgery and at risk of malnutrition (Nutritional Risk Screening Assessment 2002 score ≥3) were randomly assigned into two groups. Oral nutritional support (Nutridrink Compact Protein, Nutricia LLC) was administered to the study group (n=55) at a rate of 250 ml/d (36 g of protein, 612 kcal) for 14 days prior to and 14 days following the surgery, in addition to the standard diet. Control group patients (n=57) were provided a standard diet. The quality of life was assessed using the Quality of Life Questionnaire Core-30. Results are presented as mean ± standard deviation. Differences were considered significant at p ≤0.05. RESULTS: Throughout the entire observation period, the study group exhibited superior growth indicators in terms of general health status, physical, and role functioning than the control group (p 0.05). The study group patients exhibited a propensity toward improved emotional functioning, and by the end of the study, weakness and insomnia were less pronounced (p 0.05). Other indicators did not exhibit any significant variations. CONCLUSION: Нigh-protein perioperative oral nutrition supplements exert a positive impact on the quality of life of non-small cell lung cancer patients.
- 1 November 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (4) , 211-222
Open AccessImpact of perioperative high-protein nutritional support on the quality of life of patients with primary lung cancer: a Russian prospective multicenter comparative study (NUTRILUNC study)
BACKGROUND: Individuals over the age of 70 comprise over half of operable patients with stage 0–IIIA lung cancer. In the early postoperative period of this cohort, pain, fatigue, insomnia, and/or mood disturbances are the four most common symptoms, which can significantly diminish quality of life and functional status. Perioperative nutritional support in such patients, which enhances exercise tolerance, can have a positive impact on their quality of life and socialization. AIM: To assess the effect of perioperative nutritional support using high-protein oral nutrition supplements on the general health and quality of life of non-small cell lung cancer patients during the postoperative period. MATERIALS AND METHODS: Patients with primary non-small cell lung cancer (n=112, 69 males), aged 57.2±8.2, who were awaiting lung surgery and at risk of malnutrition (Nutritional Risk Screening Assessment 2002 score ≥3) were randomly assigned into two groups. Oral nutritional support (Nutridrink Compact Protein, Nutricia LLC) was administered to the study group (n=55) at a rate of 250 ml/d (36 g of protein, 612 kcal) for 14 days prior to and 14 days following the surgery, in addition to the standard diet. Control group patients (n=57) were provided a standard diet. The quality of life was assessed using the Quality of Life Questionnaire Core-30. Results are presented as mean ± standard deviation. Differences were considered significant at p ≤0.05. RESULTS: Throughout the entire observation period, the study group exhibited superior growth indicators in terms of general health status, physical, and role functioning than the control group (p 0.05). The study group patients exhibited a propensity toward improved emotional functioning, and by the end of the study, weakness and insomnia were less pronounced (p 0.05). Other indicators did not exhibit any significant variations. CONCLUSION: Нigh-protein perioperative oral nutrition supplements exert a positive impact on the quality of life of non-small cell lung cancer patients.
- Open Access
- 2 September 2023
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (4) , 605-615
The Non-Targeted Abscopal Effect in High Dose-Rate Radiobiology
During the response to ionizing radiation, several mechanisms interact, including direct damage of DNA, vascular endothelial cell apoptosis, immune cell death, and the development of non-target effects. The contribution of each of these mechanisms to the overall biological response varies depending on the radiation regimen, and primary on the dose per fraction. At high-dose irradiation and significant doses per fraction, indirect (vascular, immune, and non-targeted) tumor cell death becomes of primary importance. Non-targeted radiobiological effects, observed in cells and tissues not directly exposed to ionizing radiation, are insufficiently studied, exhibit poor predictability, and have garnered growing interest among researchers. These effects contribute to the evolving concept of modern radiobiology and can be comprehensively studied through the interrelation of three main models: linear-quadratic, vascular, and immune. The non-targeted abscopal effect, including its specific manifestation, known as the "bystander effect," involve the transmission of radiation signals (primarily apoptosis) from irradiated to non-irradiated cells via intercellular contacts and mediator secretion. This occurs due to intense immune system stimulation caused by massive expression of tumor antigens. Non-targeted effects can have both positive (radioprotective) and more commonly negative (radiosensitizing) influences. The low frequency of abscopal effects is partly attributed to the suppressive influence of the tumor microenvironment. Understanding the mechanisms behind these radiobiological phenomena facilitates exploring and implementing combined approaches involving radiation, immunotherapy, and chemotherapy to achieve synergistic effects. При реализации ответа на ионизирующее излучение происходит взаимодействие нескольких механизмов: прямого повреждения генетического аппарата, сосудистого эндотелиального апоптоза, иммунной гибели клеток и развитие немишенных эффектов. Вклад в совокупный биологический ответ каждого из этих механизмов меняется в зависимости от режима облучения, и прежде всего от дозы за фракцию. При высокодозном облучении и значительных дозах за фракцию ведущее значение приобретает непрямая (сосудистая, иммунная и немишенная) гибель опухолевых клеток. Немишенные радиобиологические эффекты, развивающиеся в клетках и тканях, которые не подвергались непосредственному воздействию ионизирующего излучения, являются недостаточно изученными, мало предсказуемыми и вызывают возрастающий интерес исследователей. Эти эффекты служат одной из причин изменения концепции современной радиобиологии и могут быть полноценно изучены на основе взаимосвязи трех основных моделей: линейно-квадратичной, сосудистой и иммунной. Немишенный абскопальный эффект и его частное проявление — «эффект свидетеля» — характеризуются передачей радиационных сигналов (прежде всего апоптоза) от облученных клеток необлученным, по крайней мере двумя механизмами: межклеточными контактами и секрецией медиаторов в результате интенсивной стимуляции иммунной системы при массированной экспрессии опухолевых антигенов. Немишенные эффекты могут оказывать как положительное (радиопротекторное), так и, чаще, отрицательное (радиосенсибилизирующее) влияние. Невысокая частота асбкопальных эффектов отчасти связана с супрессивным воздействием опухолевого микроокружения. Понимание механизмов реализации радиобиологических феноменов позволяет активно исследовать и внедрять различные сочетания облучения с иммунотерапией и химиотерапией для достижения синергетического эффекта.
- 2 September 2023
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (4) , 605-615
Open AccessThe Non-Targeted Abscopal Effect in High Dose-Rate Radiobiology
During the response to ionizing radiation, several mechanisms interact, including direct damage of DNA, vascular endothelial cell apoptosis, immune cell death, and the development of non-target effects. The contribution of each of these mechanisms to the overall biological response varies depending on the radiation regimen, and primary on the dose per fraction. At high-dose irradiation and significant doses per fraction, indirect (vascular, immune, and non-targeted) tumor cell death becomes of primary importance. Non-targeted radiobiological effects, observed in cells and tissues not directly exposed to ionizing radiation, are insufficiently studied, exhibit poor predictability, and have garnered growing interest among researchers. These effects contribute to the evolving concept of modern radiobiology and can be comprehensively studied through the interrelation of three main models: linear-quadratic, vascular, and immune. The non-targeted abscopal effect, including its specific manifestation, known as the "bystander effect," involve the transmission of radiation signals (primarily apoptosis) from irradiated to non-irradiated cells via intercellular contacts and mediator secretion. This occurs due to intense immune system stimulation caused by massive expression of tumor antigens. Non-targeted effects can have both positive (radioprotective) and more commonly negative (radiosensitizing) influences. The low frequency of abscopal effects is partly attributed to the suppressive influence of the tumor microenvironment. Understanding the mechanisms behind these radiobiological phenomena facilitates exploring and implementing combined approaches involving radiation, immunotherapy, and chemotherapy to achieve synergistic effects. При реализации ответа на ионизирующее излучение происходит взаимодействие нескольких механизмов: прямого повреждения генетического аппарата, сосудистого эндотелиального апоптоза, иммунной гибели клеток и развитие немишенных эффектов. Вклад в совокупный биологический ответ каждого из этих механизмов меняется в зависимости от режима облучения, и прежде всего от дозы за фракцию. При высокодозном облучении и значительных дозах за фракцию ведущее значение приобретает непрямая (сосудистая, иммунная и немишенная) гибель опухолевых клеток. Немишенные радиобиологические эффекты, развивающиеся в клетках и тканях, которые не подвергались непосредственному воздействию ионизирующего излучения, являются недостаточно изученными, мало предсказуемыми и вызывают возрастающий интерес исследователей. Эти эффекты служат одной из причин изменения концепции современной радиобиологии и могут быть полноценно изучены на основе взаимосвязи трех основных моделей: линейно-квадратичной, сосудистой и иммунной. Немишенный абскопальный эффект и его частное проявление — «эффект свидетеля» — характеризуются передачей радиационных сигналов (прежде всего апоптоза) от облученных клеток необлученным, по крайней мере двумя механизмами: межклеточными контактами и секрецией медиаторов в результате интенсивной стимуляции иммунной системы при массированной экспрессии опухолевых антигенов. Немишенные эффекты могут оказывать как положительное (радиопротекторное), так и, чаще, отрицательное (радиосенсибилизирующее) влияние. Невысокая частота асбкопальных эффектов отчасти связана с супрессивным воздействием опухолевого микроокружения. Понимание механизмов реализации радиобиологических феноменов позволяет активно исследовать и внедрять различные сочетания облучения с иммунотерапией и химиотерапией для достижения синергетического эффекта.